Bank of Montreal
ARIA

Bank of Montreal’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Bank of Montreal’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,460
Closed -$47K – 4355
2016
Q4 		$47K Sell
3,460
-5,732
-62% -$69K ﹤0.01% 3133
2016
Q3 		$126K Buy
9,192
+6,620
+257% +$66.5K ﹤0.01% 2659
2016
Q2 		$19K Sell
2,572
-3,329
-56% -$25K ﹤0.01% 3415
2016
Q1 		$37K Sell
5,901
-20,568
-78% -$115K ﹤0.01% 3178
2015
Q4 		$166K Buy
26,469
+19,761
+295% +$130K ﹤0.01% 2524
2015
Q3 		$40K Buy
6,708
+1,708
+34% +$13.2K ﹤0.01% 3009
2015
Q2 		$42K Hold
5,000
– – ﹤0.01% 3065
2015
Q1 		$42K Sell
5,000
-5,300
-51% -$39.2K ﹤0.01% 2993
2014
Q4 		$70K Buy
10,300
+4,550
+79% +$28.5K ﹤0.01% 2931
2014
Q3 		$31K Sell
5,750
-20,000
-78% -$117K ﹤0.01% 3315
2014
Q2 		$164K Hold
25,750
– – ﹤0.01% 2592
2014
Q1 		$207K Sell
25,750
-4,200
-14% -$32.7K ﹤0.01% 2488
2013
Q4 		$204K Sell
29,950
-142,462
-83% -$769K ﹤0.01% 2235
2013
Q3 		$3.17M Sell
172,412
-222
-0.1% -$4.31K ﹤0.01% 956
2013
Q2 		$3.02M Buy
+172,634
New +$3.06M 0.01% 935

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.59% 1-Year Est. Return

Bank of Montreal's ARIA Position: Q1 2017 in Review

Bank of Montreal sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 3,460 shares — an estimated $47K sold.

Bank of Montreal first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $3.17M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Bank of Montreal reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Bank of Montreal sold 3,460 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $47K.
  • Bank of Montreal first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Bank of Montreal's Ariad Pharmaceuticals Inc position peaked at $3.17M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Bank of Montreal's 13F filing for Q1 2017, filed 11 Apr 2017.